INOVIQ Share Price Climbs 23% Amid Clinical Study Progress

Share Price Surge Traced to External Research Note

INOVIQ Limited (ASX:IIQ) has addressed a sharp rise in its share price on 17 June 2026, clarifying that it holds no undisclosed price-sensitive information. The company attributes the jump from $0.295 to a high of $0.365 during the day to a third-party research note published earlier that day, which highlighted INOVIQ’s upcoming clinical milestones and investment thesis.

Clinical Study Milestones Driving Investor Interest

The third-party note drew attention to the imminent completion of key phases in INOVIQ’s EXO-OC ovarian cancer test clinical study. As outlined in the March 2026 quarterly update, the company is conducting a large, blinded, retrospective case-control study involving approximately 2,000 biobanked plasma samples. This study aims to validate the test’s sensitivity, specificity, and overall accuracy across various ovarian cancer stages and related high-risk groups.

Sample analysis began in April 2026, and INOVIQ confirmed that the ovarian cancer-control group is on track for completion by the end of June 2026. This milestone represents a significant near-term inflection point, with further analysis of high-risk and confounding disease groups scheduled for the second half of 2026.

Reaffirmation of Compliance and Board Oversight

INOVIQ explicitly denied holding any material information not already disclosed to the market, confirming full compliance with ASX Listing Rule 3.1. The company also confirmed that its response to the ASX price query was authorised by the board, underscoring its commitment to transparency and regulatory adherence.

This clarification comes amid heightened investor attention on INOVIQ’s clinical progress and potential commercialisation of the EXO-OC test, which has been a focal point of the company’s recent R&D efforts and capital raises. The company’s ongoing developments in exosome-based diagnostics and therapeutics continue to attract market interest.